Cancer Chemotherapy and Pharmacology

, Volume 82, Issue 5, pp 787–793 | Cite as

Comparative study of the effects of venlafaxine and duloxetine on chemotherapy-induced peripheral neuropathy

  • Negin FarshchianEmail author
  • Avisa Alavi
  • Sahel Heydarheydari
  • Nasrin Moradian
Original Article



One of the complications of chemotherapy is peripheral neuropathy. Various studies have shown that potent norepinephrine and serotonin reuptake inhibitors such as gabapentin, venlafaxine and duloxetine have therapeutic effects on neuropathy. The aim of this study was to compare the effects of venlafaxine vs. duloxetine on chemotherapy-induced peripheral neuropathy.


In this clinical trial, cancer patients who were suffering from chemotherapy-induced peripheral neuropathy comprised the study population. They were randomly assigned to three pharmacotherapy groups including venlafaxine, duloxetine and placebo. Cranial, sensory, motor neuropathies as well as neuropathic pain were evaluated on day 1, week 2, and week 4 after enrollment.


Grade of cranial, motor, sensory and neuropathic pain decreased significantly in venlafaxine and duloxetine groups. This reduction was more considerable in duloxetine group compared to venlafaxine group (P < 0.05).


Duloxetine seems to be more effective than venlafaxine in decreasing the symptoms of chemotherapy-induced peripheral neuropathy. Duloxetine was more effective than venlafaxine in decreasing motor neuropathy and neuropathic pain grade.


Chemotherapy-induced neuropathy Venlafaxine Duloxetine 



The authors gratefully acknowledge the Research Council of Kermanshah University of Medical Sciences and Clinical Research Development Center, Imam Reza Hospital for the financial support and cooperation. This work (approved research plan No: 95128) was performed in partial fulfillment of the requirements for Med. D. of Avisa Alavi, in Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran.


This study was funded by Research Council of Kermanshah University of Medical Sciences (Grant Number 95128).

Compliance with ethical standards

Conflict of interest

Authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in the study involving human participants were in accordance with the ethical standards of the Research Council of Kermanshah University of Medical Sciences and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.


  1. 1.
    Holley SK (2000) Evaluating patients’ distress from cancer related fatigue: an instrument development study. Oncol Nurs Forum 27(9):1425–1430PubMedGoogle Scholar
  2. 2.
    Park SB, Goldstein D, Krishnan AV, Lin CS, Friedlander ML, Cassidy J, Koltzenburg M, Kiernan MC (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin 63(6):419–437CrossRefGoogle Scholar
  3. 3.
    Zhang X, Chen WW, Huang WJ (2017) Chemotherapy-induced peripheral neuropathy. Biomed Rep 6(3):267–271CrossRefGoogle Scholar
  4. 4.
    Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772–781CrossRefGoogle Scholar
  5. 5.
    Iop A, Manfredi AM, Bonura S (2004) Fatigue in cancer patients receiving chemotherapy: an analysis of published studies. Ann Oncol 15(5):712–720CrossRefGoogle Scholar
  6. 6.
    Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP (2014) Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 6:135–147CrossRefGoogle Scholar
  7. 7.
    Branda RF, Naud SJ, Brooks EM, Chen Z, Muss H (2004) Effect of vitamin B12, folate, and dietary supplements on breast carcinoma chemotherapy–induced mucositis and neutropenia. Cancer 101(5):1058–1064CrossRefGoogle Scholar
  8. 8.
    Farquhar-Smith P (2011) Chemotherapy-induced neuropathic pain. Curr Opin Support Palliat Care 5(1):1–7CrossRefGoogle Scholar
  9. 9.
    Biedrzycki BA (2010) Peripheral neuropathy. In: Brown CG (ed) A guide to oncology symptom management. Oncology Nursing Society, Pittsburgh, pp. 405–421Google Scholar
  10. 10.
    Aziz MT, Good BL, Lowe DK (2014) Serotonin-norepinephrine reuptake inhibitors for the management of chemotherapy-induced peripheral neuropathy. Ann Pharmacother 48(5):626–632CrossRefGoogle Scholar
  11. 11.
    Rowbotham MC, Goli V, Kunz NR, Lei D (2004). Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain 110(3):697–706CrossRefGoogle Scholar
  12. 12.
    Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25(6):871–880CrossRefGoogle Scholar
  13. 13.
    Pachman DR, Barton DL, Watson JC, Loprinzi CL (2011) Chemotherapy-induced peripheral neuropathy: prevention and treatment. Clin Pharmacol Ther 90(3):377–387CrossRefGoogle Scholar
  14. 14.
    Bril V, England JD, Franklin GM et al (2011) Evidence-based guideline: treatment of painful diabetic neuropathy—report of the American association of neuromuscular and electrodiagnostic medicine, the American academy of neurology, and the American academy of physical medicine & rehabilitation. Muscle Nerve 43(6):910–917CrossRefGoogle Scholar
  15. 15.
    Dyck PJ (2005) Peripheral neuropathy. Elsevier Inc., AmsterdamGoogle Scholar
  16. 16.
    Kautio AL. Chemotherapy-induced neuropathy: prevention and treatment. Helsinki.2012Google Scholar
  17. 17.
    Smith EM, Pang H, Cirrincione C, Fleishman S, Paskett ED, Ahles T et al (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA 309(13):1359–1367CrossRefGoogle Scholar
  18. 18.
    Esin E, Yalcin S (2014) Neuropathic cancer pain: what we are dealing with? How to manage it? OncoTargets Ther 7:599–618Google Scholar
  19. 19.
    Piccolo J, Kolesar JM (2014) Prevention and treatment of chemotherapy-induced peripheral neuropathy. Am J Health Syst Pharm 71(1):19–25CrossRefGoogle Scholar
  20. 20.
    Shahid A, Wilkinson K, Marcu S, Shapiro CM (2011) Brief pain inventory (BPI). InSTOP, THAT and one hundred other sleep scales. Springer, New York. pp 81–88Google Scholar
  21. 21.
    Sheehan DV, Harnett-Sheehan K, Raj BA (1996) The measurement of disability. ‎Int Clin Psychopharmacol 11:89–95CrossRefGoogle Scholar
  22. 22.
    Simão DA, Murad M, Martins C, Fernandes VC, Captein KM, Teixeira AL (2015) Chemotherapy-induced peripheral neuropathy: review for clinical practice. Revista Dor 16(3):215–220CrossRefGoogle Scholar
  23. 23.
    Dutta K, Garg R (2016) Role of duloxetine as adjuvant in chemotherapy induced peripheral neuropathic pain-an update. J Addict Med Ther Sci 2(1):010–012. CrossRefGoogle Scholar
  24. 24.
    Yang YH, Lin JK, Chen WS, Lin TC, Yang SH, Jiang JK, Chang SC, Lan YT, Lin CC, Yen CC, Tzeng CH (2012) Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. Support Care Cancer 20(7):1491–1497CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Negin Farshchian
    • 1
    • 2
    Email author
  • Avisa Alavi
    • 2
  • Sahel Heydarheydari
    • 3
  • Nasrin Moradian
    • 2
    • 4
  1. 1.Department of Radiation Oncology, Faculty of MedicineKermanshah University of Medical SciencesKermanshahIran
  2. 2.Clinical Research Development CenterImam Reza HospitalKermanshahIran
  3. 3.Department of Medical Physics, Faculty of MedicineKermanshah University of Medical SciencesKermanshahIran
  4. 4.Department of Neurology, Faculty of MedicineKermanshah University of Medical SciencesKermanshahIran

Personalised recommendations